Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors

作     者：Shi-Yong Sun Shi-Yong Sun

作者机构：Department of Hematology and Medical OncologyEmory University School of Medicine and Winship Cancer Institute of Emory UniversityAtlantaGA 30322USA 

出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)

年 卷 期：2022年第16卷第5期

页      面：701-713页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Some of work done in my laboratory were supported by the NIH/NCI R01 CA223220 R01 CA245386 UG1CA233259 awards and Emory University Winship Cancer Institute lung cancer pilot funds 

主　　题：acquired resistance EGFR inhibitor apoptosis lung cancer 

摘      要：A significant clinical challenge in lung cancer treatment is management of the inevitable acquired resistance to third-generation epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(EGFR-TKIs),such as osimertinib,which have shown remarkable success in the treatment of advanced NSCLC with EGFR activating mutations,in order to achieve maximal response duration or treatment *** is a major type of programmed cell death tightly associated with cancer development and *** of apoptosis is considered a key hallmark of cancer and acquisition of apoptosis resistance is accordingly a key mechanism of drug acquired resistance in cancer *** has been clearly shown that effective induction of apoptosis is a key mechanism for third generation EGFR-TKIs,particularly osimertinib,to exert their therapeutic efficacies and the development of resistance to apoptosis is tightly associated with the emergence of acquired ***,restoration of cell sensitivity to undergo apoptosis using various means promises an effective strategy for the management of acquired resistance to third generation EGFR-TKIs.